Assessing Atherosclerotic Cardiovascular Disease Risk with Advanced Lipid Testing: State of the Science

Area of Science:

• Cardiology and Atherosclerosis Research
• Lipid Metabolism and Cardiovascular Risk Assessment

Background:

• Cardiovascular disease (CVD) is the leading cause of global mortality and disability.
• Rising obesity and diabetes rates pose a significant threat to cardiovascular health.
• Standard lipid panels are crucial but can be insufficient for accurate risk assessment.

Purpose of the Study:

• To evaluate the role of advanced lipid biomarkers in cardiovascular disease risk stratification.
• To explore the utility of novel atherogenic lipoprotein measures beyond standard lipid panels.
• To assess the potential of these biomarkers in guiding lipid-lowering therapy.

Main Methods:

• Review of advances in understanding atherosclerosis and development of lipid-based biomarkers.
• Analysis of the clinical implementation challenges of novel lipid biomarkers.
• Consideration of additional measures of atherogenic lipoproteins and their surrogates.

Main Results:

• Novel lipid biomarkers can help discriminate cardiovascular disease risk when standard tests are unclear.
• Implementation of these advanced biomarkers is hindered by literature discrepancies, standardization issues, cost, and accessibility.
• Additional lipoprotein measures offer enhanced risk assessment and therapy guidance.

Conclusions:

• Advanced lipid biomarkers provide valuable insights beyond the standard lipid panel for cardiovascular risk.
• Overcoming implementation barriers is crucial for widespread clinical adoption.
• These biomarkers promise more precise risk assessment and optimized lipid-lowering treatment strategies.